Low-dose methotrexate and serious adverse events among older adults with chronic kidney disease
Muanda FT, Blake PG, Weir MA, Ahmadi F, McArthur E, Sontrop JM, Urquhart BL, Kim RB, Garg AX. JAMA Netw Open. 2023; 6(11):e2345132. Epub 2023 Nov 27.
Objective — To assess compliance with a step-up approach to proton pump inhibitor (PPI) therapy before implementation of a new provincial policy to promote histamine-type 2 receptor antagonist (H2RA) use before PPI therapy.
Design — Population-based, retrospective, open cohort study using prescribing and medical procedure data from January 1, 1995, to April 30, 1999.
Setting — Health administration databases for the universal health care system in Ontario.
Participants — Approximately 1.4 million residents of Ontario older than 65 years.
Main Outcome Measures — Proportion of patients who received a trial of H2RA therapy or gastrointestinal diagnostic testing 12 months before starting PPI therapy in 1996.
Results — Among the 25,870 patients who met study criteria in 1996, about 63% had received H2RAs 12 months before starting PPI therapy and 73% had had a trial of H2RAs or gastrointestinal diagnostic testing. Repeat analysis for January through April 1999, following the new policy implementation, showed that about 72% of patients had had a trial of H2RAs within 12 months of starting PPI therapy.
Conclusion — A modest gain (9%) in compliance with using H2RA therapy within 12 months before starting PPI therapy was seen following introduction of the step-up intervention. In future, costs and benefits of potential interventions should be carefully considered before implementing new policies.
Mamdani MM, Tu K, Jaakkimainen L, Bica A, Hux J. Can Fam Physician. 2001; 47:531-5.
The ICES website uses cookies. If that’s okay with you, keep on browsing, or learn more about our Privacy Policy.